Case 8:15-cv-00865-DOC-SHK Document 890 Filed 12/29/21 Page 1 of 11 Page ID #:70912

3 4

5

8

9

7

10 11

12

13

18 19

20

21

22 23

24

26

28

WHEREAS, an action is pending before this Court entitled *Hsingching Hsu v*. Puma Biotechnology, Inc., et al., No. 8:15-cv-00865-DOC-SHK (the "Litigation");

WHEREAS, Lead Plaintiff having made application, pursuant to Federal Rule of Civil Procedure ("Rule") 23(e), for an order preliminarily approving the settlement of this Litigation, in accordance with a Stipulation of Settlement dated December 1, 2021 (the "Stipulation"), which sets forth the terms and conditions for a proposed settlement of the Litigation and for dismissal of the Litigation with prejudice upon the terms and conditions set forth therein; and the Court having read and considered the Stipulation; and

WHEREAS, unless otherwise defined, all terms used herein have the same meanings as set forth in the Stipulation.

NOW, THEREFORE, IT IS HEREBY ORDERED:

- After a preliminary review, the Settlement appears to be fair, reasonable, and adequate. The Settlement: (a) resulted from arm's-length negotiations; and (b) is sufficient in amount to warrant (i) notice thereof as set forth below; and (ii) a full hearing on the Settlement. Accordingly, the Court does hereby preliminarily approve the Stipulation and the Settlement set forth therein, subject to further consideration at the Settlement Hearing described below.
- 2. A hearing (the "Settlement Hearing") shall be held before this Court on April 11, 2022, at 8:00 a.m., at the United States District Court for the Central District of California, Ronald Reagan Federal Building and U.S. Courthouse, 411 West Fourth Street, Courtroom 9D, Santa Ana, CA 92701, for the following purposes:
- to determine whether the Settlement is fair, reasonable, and adequate, and should be approved by the Court;
- to finally determine whether Settlement Judgment as provided (b) under the Stipulation should be entered and to determine whether the release by Lead Plaintiff and the Class of the Released Defendant Parties as set forth in the Stipulation,

3 4

5

6

7

10

8

11 12

13

15

14

16

18

19

20 21

22 23

24

25 26

27 28 should be ordered, along with a permanent injunction barring efforts to bring any Released Claims extinguished by the Settlement;

- to consider the application of Lead Counsel for an award of (c) attorneys' fees and expenses, and any application for an award to Lead Plaintiff;
 - to consider any objections; and (d)
 - to rule upon such other matters as the Court may deem appropriate. (e)
- 3. The Court may adjourn the Settlement Hearing without further notice to the members of the Class, and reserves the right to approve the Settlement with such modifications as may be agreed upon or consented to by the parties and without further notice where to do so would not impair Class members' rights in a manner inconsistent with Rule 23 and due process of law. The Court further reserves the right to enter its Settlement Judgment approving the Settlement and dismissing the Litigation on the merits and with prejudice, regardless of whether it has awarded attorneys' fees and expenses or made an award to Lead Plaintiff.
- The Court approves, as to form and content, the Notice and the Summary Notice, annexed hereto as Exhibits A-1 and A-2, respectively, and finds that the mailing and distribution of the Notice and publishing of the Summary Notice, substantially in the manner and form set forth in ¶6-7 of this Order, meet the requirements of Rule 23 and due process, §21D of the Securities Exchange Act of 1934, 15 U.S.C. §78u-4(a)(7), as amended by the PSLRA, the rules of this Court, and any other applicable law, and is the best notice practicable under the circumstances and shall constitute due and sufficient notice to all persons entitled thereto.
- 5. The firm of Gilardi & Co. LLC (the "Claims Administrator") is hereby appointed to supervise and administer the notice procedure as well as the Settlement as more fully set forth below.
- Lead Counsel, through the Claims Administrator, shall commence 6. mailing the Notice, substantially in the form annexed hereto, within ten (10) business days after the Court signs this Order (the "Notice Date"), or by January 14, 2022, by

3 4

5

6 7

8

9 10

11

13

14

16

18

19

20

21

22

23

24

25

26

27 28 first-class mail to all validated claimants, and the Notice shall be posted on the Settlement website at www.PumaBioSecuritiesLitigation.com.

- 7. Not later than seven (7) calendar days after the Notice Date, the Claims Administrator shall cause the Summary Notice to be published once in the national edition of *The Wall Street Journal* and once over a national newswire service.
- 8. At least seven (7) calendar days prior to the Settlement Hearing, Lead Counsel shall serve on Defendants' counsel and file with the Court proof, by affidavit or declaration, of such mailing and publishing.
- Lead Counsel may make non-material edits to the Notice and Summary 9. Notice without Court approval.
- 10. Any member of the Class may enter an appearance in the Litigation, at their own expense, individually or through counsel of their own choice. If they do not enter an appearance, they will be represented by Lead Counsel.
- The Court will consider comments or objections to the Settlement, 11. including Lead Counsel's request for an award of attorneys' fees and expenses, including Lead Plaintiff's expenses as provided for by 15 U.S.C. §78u-4(a)(4), only if such comments or objections and any supporting papers are served by hand or sent by first-class mail, and are received at least twenty-one (21) calendar days prior to the Settlement Hearing, or March 21, 2022:

Counsel for Lead Plaintiff

Robbins Geller Rudman & Dowd LLP Tor Gronborg 655 West Broadway, Suite 1900 San Diego, CA 92101

Counsel for Defendants

Latham & Watkins LLP 12670 High Bluff Drive San Diego, CA 92130

Those comments or objections and any supporting papers must also be filed with the Clerk of the United States District Court for the Central District of California, Ronald Reagan Federal Building and United States Courthouse, 411 West Fourth Street, Santa Ana, CA 92701, at least twenty-one (21) calendar days prior to the Settlement Hearing, or March 21, 2022. Attendance at the Settlement Hearing is not necessary but any person wishing to be heard orally in opposition to the Settlement or application for attorneys' fees and expenses or an award to Lead Plaintiff are required to indicate in their written objection whether they intend to appear at the Settlement Hearing. The notice of objection must include copies of any papers, briefs, or other documents upon which the objection is based, and the objector's signature, even if represented by counsel. In addition, the objection must state whether it applies only to the objector, to a specific subset of the Class, or to the entire Class, and also state with specificity the grounds for the objection. The objector must also identify all other objections to any class action settlements submitted by the objector or his, her or its counsel. Any member of the Class who does not make his, her or its objection in the manner provided shall be deemed to have waived such objection and shall forever be foreclosed from making any objection to the Settlement or award of attorneys' fees and expenses to Lead Counsel or expenses of the Lead Plaintiff unless otherwise ordered by the Court.

- 12. All funds held by the Escrow Agent shall be deemed and considered to be in *custodia legis* of the Court, and shall remain subject to the jurisdiction of the Court, until such time as such funds shall be distributed pursuant to the Stipulation and/or further order(s) of the Court.
- 13. All opening briefs and supporting documents in support of the Settlement, and any application by counsel for the Lead Plaintiff for attorneys' fees and expenses or by Lead Plaintiff for its expenses shall be filed and served no later than thirty-five (35) calendar days before the Settlement Hearing, or March 7, 2022. Replies to any objections shall be filed and served at least seven (7) calendar days prior to the Settlement Hearing, or April 4, 2022.

27

1

2

3

4

5

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

- 14. Neither Defendants nor the Released Defendant Parties shall have any responsibility for any application for attorneys' fees or expenses submitted by Lead Counsel or Lead Plaintiff, and such matters will be considered separately from the fairness, reasonableness, and adequacy of the Settlement. Any order or proceeding relating to the application for attorneys' fees or expenses, or any appeal from any order relating thereto or reversal or modification thereof, shall not operate to terminate or cancel the Stipulation, or affect or delay the finality of the Settlement Judgment approving the Stipulation and the settlement of the Litigation.
- 15. If the Stipulation and the Settlement set forth therein is not approved or consummated for any reason whatsoever, the Stipulation and Settlement and all proceedings had in connection therewith shall be without prejudice to the rights of the Settling Parties status *quo ante*.
- 16. Pending final determination of whether the proposed Settlement should be approved, neither the Lead Plaintiff, nor any Class member, directly or indirectly, representatively, or in any other capacity, shall commence or prosecute against any of the Released Defendant Parties, any action or proceeding in any court or tribunal asserting any of the Released Claims.
- 17. The Court retains exclusive jurisdiction over the Litigation to consider all further matters arising out of or connected with the Settlement.
- 18. The Court's orders entered during this Litigation relating to the confidentiality of information shall survive this Settlement.

IT IS SO ORDERED.

DATED: <u>December 29, 202</u>1

THE HONORABLE DAVID O. CARTER UNITED STATES DISTRICT JUDGE

plavid O. Carter

EXHIBIT A-1

0865-DOC-SHK

LEGAL NOTICE

<<B<<<<< See other side for details

Postal Service: Please Do Not Mark Barcode PUY-«Claim8»-«CkDig»

Document 890 #:70919

Claim ID: «Claim8»

PIN: «PIN»

«FirstNAME» «LastNAME»

Filed 12/29/21

Page 8

«City», «State»«FProv» «Zip»«FZip» «Addr1» «Addr2»

«FCountry»

Notice of Class Action Settlement

You are receiving this notice because your claim in the Puma Biotechnology, Inc. securities litigation has been validated and you are entitled to recover for your losses in accordance with the jury verdict. You can identify that your claim has been validated and the amount of your damages and prejudgment interest at the websiter

listed below. You do not need to do anything in order to receive your share of the settlement.

Amount"). The Settlement Amount represents the complete amount of claimed damages and prejudgment The parties have agreed to a proposed settlement of the litigation for \$54,248,374.00 (the "Settlement

claims in the litigation. Based on your previously submitted claim form and the damages calculations performed by the Claims Administrator, you will receive 100% of your damages and prejudgment interest less: (i) *pun pro rata share of any Court awarded attorney fees and litigation expenses and any Court award to the Damage Plaintiff; (ii) settlement administration expenses; and (iii) taxes and tax expenses. Class Counsel the prosecuted this case on a wholly contingent basis and will apply to the Court for: (i) an award of attorneys Asco of 25% of the Settlement Amount; (ii) payment of litigation expenses paid or incurred by Class Counsel in an amount not to exceed \$3,100,000; and (iii) an award to Lead Plaintiff in an amount not to exceed \$100,000 pursuant to 15 U.S.C. \$78u-4(a)(4). The requested attorneys' fees and expenses represent approximately \$1.3 interest due to validated claims under the jury verdict. If approved, the settlement will finally resolveath

You have the right to object to the application for Class Counsel fees or expenses and/or the application for the

Lead Plaintiff award. Any objection is due by XXX. For more information on filing an objection, please go to

If you have any questions, you can contact Class Counsel, Tor Gronborg, at 1-619-231-1058 or visit:

www.pumabiosecuritieslitigation.com

Page

EXHIBIT A-2

HSINGCHING HSU, Individually #.70922No. 8:15-cv-00865-AG-SHK and on Behalf of All Others Similarly CLASS ACTION

Plaintiff,
vs.

PUMA BIOTECHNOLOGY, INC., et al., {

UNITED STATES DISTRICT COURT CENTRAL DISTRICT OF CALIFORNIA

Notice of Class Action Settlement

You are hereby notified, pursuant to Rule 23 of the Federal Rules of Civil Procedure and Order of the United States District Court for the Central District of California, that a Settlement has been proposed in the above-captioned action. You can identify if your claim has been validated and the amount of

Defendants.

your damages and prejudgment interest at the website listed below. If you have submitted a validated claim, you do not need to do anything in order to receive your share of the settlement.

The parties have agreed to a proposed settlement of the litigation for

\$54,248,374.00 (the "Settlement Amount"). The Settlement Amount represents the complete amount of claimed damages and prejudgment interest due to validated claims under the jury verdict. If approved, the settlement will finally resolve all claims in the litigation. Based on your previously submitted claim form and the damages calculations performed by the Claims Administrator, you

will receive 100% of your damage's and prejudgment interest less:(i) your pro rata share of any Court awarded attorney fees and litigation expenses and any Court award to the Lead Plaintiff; (ii) settlement administration expenses; and (iii) taxes and tax expenses. Class Counsel have prosecuted this case on a wholly contingent basis and will apply to the Court for: (i) an award of attorneys' fees of 25% of the Settlement Amount; (ii) payment of litigation expenses paid on incurred by Class Counsel in an amount not to exceed \$3,100,000; and (iii) an award to Lead Plaintiff in an amount not to exceed \$100,000, pursuant to

15 U.S.C. §78u-4(a)(4). The requested attorneys' fees and expenses represent approximately \$1.33 per share.

You have the right to object to the application for Class Counsel fees or expenses and/or the application for the Lead Plaintiff award. Any objection is due by XXX. For more information on filing an objection, please go to the website listed below.

If you have any questions, you can contact Class Counsel, Tor Gronborg, at 1-619-231-1058 or visit:

www.pumabiosecuritieslitigation.com